Oxcarbazepine and its active metabolite, (S)-licarbazepine, exacerbate seizures in a mouse model of genetic generalized epilepsy

Epilepsia

Volumn 56, Issue 1, 2015, Pages e6-e9

  Kim, Tae Hwan ^a   Reid, Christopher A ^a   Petrou, Steven ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antiepileptic drugs; Epilepsy; Seizure aggravation; Spike and wave

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BETA1; LICARBAZEPINE; OXCARBAZEPINE; VALPROIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIBENZAZEPINE DERIVATIVE; ESLICARBAZEPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; ELECTROCORTICOGRAPHY; ELECTRODE IMPLANTATION; GENERALIZED EPILEPSY; LOCOMOTION; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPIKE AND WAVE DISCHARGE; SPIKE WAVE; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; ELECTROENCEPHALOGRAM; GENETICS; HUMAN; MUTATION; TRANSGENIC MOUSE;

ANIMALS; ANTICONVULSANTS; BRAIN; BRAIN WAVES; CARBAMAZEPINE; DIBENZAZEPINES; DISEASE MODELS, ANIMAL; EPILEPSY, GENERALIZED; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; RECEPTORS, GABA-A; VALPROIC ACID;

EID: 84921656017     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12866     Document Type: Article

References (15)

1. Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39: 5-17.
2. Schmidt D, Elger CE,. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004; 5: 627-635.
3. Vendrame M, Khurana DS, Cruz M, et al. Aggravation of seizures and/or EEG features in children treated with oxcarbazepine monotherapy. Epilepsia 2007; 48: 2116-2120.
4. Zheng T, Clarke AL, Morris MJ, et al. Oxcarbazepine, not its active metabolite, potentiates GABAA activation and aggravates absence seizures. Epilepsia 2009; 50: 83-87.
5. de Jesus Antunes N, Wichert-Ana L, Coelho EB, et al. Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. Chirality 2013; 12: 897-903.
6. Serrano-Castro PJ, Payan-Ortiz M, Cimadevilla JM, et al. [Eslicarbazepine acetate in clinical practice. Efficacy and safety results]. Rev Neurol 2013; 56: 309-314.
7. Perucca E, Elger C, Halasz P, et al. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res 2011; 96: 132-139.
8. Bialer M, Soares-da-Silva P,. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia 2012; 53: 935-946.
9. Tan HO, Reid CA, Single FN, et al. Reduced cortical inhibition in a mouse model of familial childhood absence epilepsy. Proc Natl Acad Sci U S A 2007; 104: 17536-17541.
10. Fortuna A, Alves G, Soares-da-Silva P, et al. Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models. Epilepsy Res 2013; 107: 37-50.
11. Wallace RH, Marini C, Petrou S, et al. Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures. Nat Genet 2001; 28: 49-52.
12. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; 54: 551-563.
13. Genton P, Gelisse P, Thomas P, et al. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000; 55: 1106-1109.
14. Liu L, Zheng T, Morris MJ, et al. The mechanism of carbamazepine aggravation of absence seizures. J Pharmacol Exp Ther 2006; 319: 790-798.
15. Crunelli V, Leresche N,. Childhood absence epilepsy: genes, channels, neurons and networks. Nat Rev Neurosci 2002; 3: 371-382.